Neuronasal

Executive Summary

Neuronasal is a San Diego-based biotechnology company developing a proprietary intranasal drug delivery platform designed to bypass the blood-brain barrier and deliver therapeutics directly to the brain. The company's lead candidate uses this nose-to-brain route to deliver N-acetylcysteine (NAC) for the treatment of Parkinson's Disease and mild Traumatic Brain Injury (mTBI). Currently in late preclinical stage, Neuronasal aims to address significant unmet needs in neurological disorders where current treatments are limited by poor brain penetration. The platform's potential to enhance drug bioavailability in the central nervous system positions it as a promising approach for multiple CNS indications. With a focus on advancing its lead program toward regulatory filing, the company represents an early-stage investment opportunity in the CNS drug delivery space.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-enabling studies60% success
• Q3 2026Preclinical proof-of-concept data in Parkinson's model70% success
• H1 2027Strategic partnership or licensing deal for platform technology30% success